Long Ideas - While investors have been focusing their attention on palifosfamide and the upcoming phase III data, Ziopharm (NASDAQ:ZIOP) released some initial phase I data of Ad-RTS IL-12 … Continue Reading
Read nowLong Ideas - In separate press releases on Thursday morning, Celgene (NASDAQ:CELG) reported 3Q results and announced that Abraxane demonstrated a statistically significant improvement in Progression Free Survival (PFS) … Continue Reading
Read nowLong Ideas - Palifosfamide is a bifunctional alkylator developed by Ziopharm Oncology (NASDAQ:ZIOP) for the treatment of a number of cancers. Soft tissue sarcoma (STS) is the most … Continue Reading
Read nowLong Ideas - DARA BioSciences (NASDAQ:DARA) released some much-needed positive news Monday morning, reporting the domestic launch of Soltamox, the first oral, liquid formulation of the breast-cancer drug … Continue Reading
Read nowMost Popular - PropThink published its latest report on Keryx Biopharmaceuticals last week, and on Monday we followed up with some technical discussion. We also included QCOR in … Continue Reading
Read nowResearch - We continue to believe that shares of Elan Corp. (NYSE:ELN) are trading at a premium valuation, given ongoing speculation that partner Biogen-Idec (NASDAQ:BIIB) may acquire … Continue Reading
Read now- The FDA has raised safety concerns about tumors spotted in patients treated with the developmental LDL-lowering therapy, Kynamro. The drug is under review after a … Continue Reading
Read now